Skip to main content
Quest Diagnostics

Congenital Melanocytic Nevi Initiated by BRAF Fusion Oncogene With Firmness, Pruritus, and Desmoplastic Stroma

Congenital Melanocytic Nevi Initiated by BRAF Fusion Oncogene With Firmness, Pruritus, and Desmoplastic Stroma

Authors: Roy SF, Agim NG, Mir A, Couts KL, Vandergriff T, Robinson WA, Bastian BC, Frieden I, Yeh I

Citation: Br J Dermatol. 2025 Feb 27:ljaf061. doi: 10.1093/bjd/ljaf061. Online ahead of print.

Specialties: Dermatology, Oncology

Disclaimer: One or more of the authors of this publication were employed at the time by DermPath Diagnostics, a subsidiary of Quest Diagnostics.

Related content

Publication
Skin Mutation Burden Drives Adaptive Immunity and Response to Immunotherapy
On-Demand Webinar
Prognostic Melanoma Molecular Testing to Inform Better Patient Care
Test FAQ
MelaNodal Predict
Publication
Using the Merlin assay for reducing sentinel lymph node biopsy complications in melanoma: a retrospective cohort study
Test FAQ
Melanoma BRAF V600E and V600K Mutation Analysis THxID

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.